9th Asia Agri-Tech Expo & Forum Opens Today, Driving Innovation in Asia-Pacific Agriculture
TAIPEI, June 11, 2025 /PRNewswire/ — Organised by Informa Markets Asia Ltd., the 2025 Asia Agri-Tech Expo & Forum officially opened today (June 11) at the ICC Tainan. The grand opening ceremony gathered key representatives from government, industry, academia, and research to witness a new milestone in the advancement of agri-tech in the Asia-Pacific region.
Distinguished guests attending the ribbon-cutting ceremony included Mr. Michael Duck, Executive Vice President of Informa Markets Asia, Deputy Mayor Yeh Tse-Shan of Tainan City Government, President Su Chih-Fen of the National Animal Industry Foundation, along with numerous prominent figures from various sectors.
This year's event features over 150 exhibitors from around the world, showcasing cutting-edge innovations in agriculture automation, smart livestock farming, precision irrigation, crop monitoring, and feed technology. In addition to the exhibition, the event presents 10 key themes across 60 professional seminars, offering in-depth discussions on emerging trends in agriculture, smart livestock farming, advanced feed technology, and biosecurity upgrades.
The three-day exhibition is expected to attract over 25,000 visitors. With Tainan serving as a central hub for agriculture and aquaculture in southern Taiwan, the event provides an ideal platform for farmers, growers, and industry professionals to explore the latest advancements. Many exhibitors are launching new products on-site, including:
TOTAL NUTRITION: Combining peptide protein, probiotics, and acidifiers to form the 'Golden Triangle' of gut health, achieving precise nutritional regulation and enhanced well-being.
WONDER VAX: Introducing the Universal Live Vaccine for Infectious Bronchitis in Chickens (TW-I, TW-II), providing dual protection against respiratory and nephritis strains, precisely targeting Taiwan's prevalent local strains (TW-I, TW-II).
YA SUH DAR: Launching a 50-inch butterfly shutter exhaust fan specifically designed for livestock farming. This large negative-pressure fan features an innovative pneumatic butterfly shutter design that effectively replaces traditional louver windows, significantly improving ventilation efficiency. It also offers excellent dustproof, corrosion-resistant, and weather-resistant performance, making it ideal for harsh environments with high temperatures and humidity.
VETNOSTRUM: Comprehensive range of veterinary medicines, health products, feed additives, and feeds for pigs, cattle, sheep, poultry, and aquatic animals.
AGRISTAR: Asia's first fully electric tractor, manufactured by Foxconn in the U.S., featuring Tesla technology and NVIDIA AI computing. Compatible with a variety of agricultural implements, it serves not only in dairy farming but also in a wide range of daily agricultural and livestock operations. This next-generation farming equipment paves the way for a net-zero carbon, sustainable agricultural future.
Ms. Grace Lee, General Manager of Informa Markets Taiwan, stated: 'Taiwan's agricultural sector boasts strong technological capabilities. Through this international platform, we foster knowledge exchange and drive innovation, enhancing global food self-sufficiency where Taiwan will play an increasingly pivotal role.'
The expo runs from June 11 to 13, open to industry professionals and related personnel free of charge. The organizers aim to foster cross-border collaboration and create a prosperous future for Asia-Pacific agriculture, paving the way for the next century of agricultural innovation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
10 hours ago
- Malaysian Reserve
Renowned Gynaecologist Joins Manipal Hospital Gurugram to Strengthen Women's Health
GURUGRAM, India, June 12, 2025 /PRNewswire/ — Manipal Hospital, one of the leading healthcare institutions in Gurugram, welcomes renowned surgeon Dr Amita Shah, Chairman & HOD, Obstetrics & Gynecology, Laparoscopy Endoscopy. Dr Shah has joined the expert team of Manipal Hospital Gurugram, to strengthen and enhance the medical expertise of healthcare delivery to the people of Gurugram. Through dedicated women's wellness and preventive health initiatives, she contributes to early detection and long-term health planning. Dr Amita Shah will further enhance Manipal Hospital's expertise with extensive knowledge and experience spanning more than 29 years in diagnosing and treating numerous complex gynaecological issues. She is an expert in procedures like 3D and Robotic-Assisted Laparoscopic Gynaecological Surgeries, Gynae Oncology – Screening & Management, Infertility & Reproductive Endocrinology and many more. Her focus is to provide preventive health, advanced management of gynaecological disorders, and fertility care through a dedicated specialty clinic that has cutting-edge technology to treat advanced gynaecological issues. She is an active member of the Indian Fertility Society (IFS) and the Indian Association of Gynae Endoscopists (IAGE). Her addition to the team strengthens the hospital's capabilities in providing comprehensive heart care. Dr Shah practices a 360-degree approach to women's health, providing care from conception through childbirth and postnatal vaccination, making Manipal Hospital a one-stop destination for maternity and reproductive care. She will play a key role in various Obstetrics and Gynecological programs such as Spandan, a parent support initiative aimed at easing the journey of parenthood through expert-led educational sessions and Manipal Sakhi, a comprehensive health card packed with exclusive patient benefits for women. Expressing his enthusiasm for joining the team, Navin Pascal, Hospital Director, Manipal Hospital, Gurugram, said, 'We are delighted to have Dr Amita Shah in our team of medical experts. With a wealth of experience in women's healthcare, Dr. Shah brings with her a deep commitment to clinical excellence and patient-centered care. Her expertise across complex gynaecological procedures, high-risk obstetrics, and holistic reproductive health makes her a valuable addition to our multidisciplinary team. With her being a part of Manipal Hospital, we will be able to deliver advanced clinical management of gynaecological disorders, including minimally invasive and robotic surgeries for faster recovery and improved outcomes. At Manipal Hospital, we are dedicated to continuously enhancing the quality and scope of our healthcare services. Her joining marks a significant step in our ongoing efforts to elevate healthcare standards in Gurugram and assure our position as a trusted leader in women's health.' About Manipal Hospitals As a pioneer in healthcare, Manipal Hospitals is among the top healthcare providers in India serving over 7 million patients annually. Its focus is to develop an affordable, high quality healthcare framework through its multispecialty and tertiary care delivery spectrum and further extend it to out of hospital care. With the completion of acquisition of Medica Synergie hospitals and AMRI Hospitals Limited (acquired in Sept 2023), the integrated network today has a pan-India footprint of 37 hospitals across 19 cities with 10,500+ beds, and a talented pool of 5,600+ doctors and an employee strength of over 18,600. Manipal Hospitals provides comprehensive curative and preventive care for a multitude of patients from around the globe. Manipal Hospitals is NABH, AAHRPP accredited and most of the hospitals in its network are NABL, ER, Blood Bank accredited and recognized for Nursing Excellence. Manipal Hospitals has also been recognised the most respected and patient recommended hospital in India through various consumer surveys Photo – – –
Malaysian Reserve
a day ago
- Malaysian Reserve
Multiple Sclerosis Market to Grow Rapidly at a CAGR of 3.8% During the Forecast Period (2025-2034)
The multiple sclerosis market is growing due to rising prevalence, earlier diagnosis, and wider access to care. Demand is fueled by advancements in DMTs and emerging BTK inhibitors, which offer targeted, high-efficacy options, especially for progressive forms with limited existing therapies. LAS VEGAS, June 11, 2025 /PRNewswire/ — Multiple sclerosis is a long-term autoimmune disorder in which the immune system mistakenly attacks the protective sheath surrounding nerves in the brain and spinal cord. This interference disrupts the flow of signals between the brain and the rest of the body, leading to symptoms such as fatigue, muscle weakness, vision disturbances, and difficulty with mobility. The severity and progression of multiple sclerosis can vary greatly among individuals. As of 2024, there were an estimated 1.6 million diagnosed cases of multiple sclerosis across the 7MM. This number is expected to increase at a CAGR of 1.4% over the forecast period from 2025 to 2034. The therapeutic landscape for multiple sclerosis has undergone a significant transformation, spurred by progress in both drug-based and supportive treatment approaches. Although MS remains without a cure, the market is seeing an expanding array of disease-modifying therapies (DMTs), greater personalization of care, and innovations in how treatments are delivered—all aimed at enhancing patient outcomes and quality of life. Pharmacologically, multiple sclerosis treatment involves both immediate and long-term strategies. For managing acute relapses, high-dose intravenous corticosteroids, most commonly methylprednisolone, continue to be the primary treatment, usually given over 3 to 5 days and followed by a course of tapering oral steroids. Learn more about the multiple sclerosis therapeutics market @ Multiple Sclerosis Drugs Market Intravenous corticosteroids, such as methylprednisolone, are effective for treating acute multiple sclerosis relapses but do not impact the long-term course of the disease. Ongoing disease management relies on disease-modifying therapies (DMTs), selected based on the severity of MS and individual patient requirements, to reduce relapse frequency and delay disability progression. While older injectable multiple sclerosis treatments like PLEGRIDY are still used, newer oral options like MAYZENT, VUMERITY, and MAVENCLAD provide greater convenience and may improve patient adherence. High-efficacy monoclonal antibodies (mAbs), including OCREVUS (now also available in a subcutaneous form), KESIMPTA, and BRIUMVI, are increasingly preferred for home-based therapy. Although LEMTRADA is a potent option, its use is restricted due to safety risks and its inclusion in the REMS program. As key multiple sclerosis drugs such as TYSABRI, TECFIDERA, AUBAGIO, and GILENYA face generic competition, pricing and access are being reshaped. In response, originator companies are shifting focus to next-generation treatments and improved formulations, such as subcutaneous versions and enhanced safety features, to retain market share. Supportive therapies also play a critical role; rehabilitation via exercise and physiotherapy can improve mobility and reduce fatigue, especially in progressive multiple sclerosis. Cognitive behavioral therapy (CBT) and mindfulness strategies help manage mood disorders like depression and anxiety, which in turn support treatment adherence. Additionally, lifestyle modifications involving diet, sleep hygiene, and vitamin D intake aid in symptom control. Assistive devices and occupational therapy further promote independence and enhance quality of life. Find out more on FDA-approved multiple sclerosis medication @ Multiple Sclerosis Treatments Multiple sclerosis treatment lacks neuroprotective and remyelinating therapies, with limited options for progressive multiple sclerosis. Current drugs focus on immune modulation but fail to reverse damage or halt progression. Diagnostic delays remain common due to nonspecific symptoms and limited biomarkers. There is a critical need for early detection tools, personalized therapies, and agents targeting neurodegeneration to improve outcomes in multiple sclerosis. The multiple sclerosis treatment pipeline remains robust, with promising candidates like Remibrutinib, Tolebrutinib, Fenebrutinib, and CNM-Au8 targeting novel mechanisms such as BTK inhibition and neuroprotection. Other multiple sclerosis drugs in the pipeline include Frexalimab (SAR441344) (Sanofi), Vidofludimus calcium (IMU-838) (Immunic Therapeutics), Masitinib (AB Science), PIPE-307 (Contineum Therapeutics), and others. These multiple sclerosis pipeline therapies reflect an increasing emphasis on progressive multiple sclerosis and remyelination to improve long-term outcomes. Discover which therapies are expected to grab major multiple sclerosis market share @ Multiple Sclerosis Treatment Market Tolebrutinib is an oral BTK inhibitor designed to penetrate the blood–brain barrier, targeting both B cells and microglia to mitigate smoldering neuroinflammation in multiple sclerosis (MS). By focusing on central nervous system (CNS) processes that drive neurodegeneration, it aims to address disease progression beyond peripheral inflammation. In March 2025, the US FDA accepted tolebrutinib for priority review as a treatment for non-relapsing secondary progressive multiple sclerosis, to slow relapse-independent disability progression. A decision is anticipated by September 2025, with a parallel evaluation ongoing in the EU. Vidofludimus calcium is an investigational oral therapy currently in Phase III trials for relapsing multiple sclerosis and Phase II for progressive multiple sclerosis. It combines DHODH inhibition for immune regulation with Nurr1 activation for potential neuroprotective effects, aiming to target key mechanisms of neurodegeneration. In April 2025, Immunic reported positive outcomes from the Phase II CALLIPER trial, supporting vidofludimus calcium's role as a Nurr1 activator in progressive multiple sclerosis patients. Fenebrutinib is an innovative, oral, reversible, non-covalent BTK inhibitor in Phase III development for MS. By modulating both adaptive and innate immune responses via B cells and microglia, it offers a dual approach to controlling disease activity and slowing disability. It is currently the only reversible BTK inhibitor in late-stage multiple sclerosis trials. The Phase III program includes FENhance 1 and 2 studies in relapsing multiple sclerosis (vs. teriflunomide) and the FENtrepid trial in primary progressive multiple sclerosis (vs. ocrelizumab), marking the first head-to-head comparison of a BTK inhibitor with an approved PPMS therapy. Regulatory submissions for both RMS and PPMS are planned for 2026. In September 2024, Roche presented 48-week results from the FENopta Phase II open-label extension at the 40th ECTRIMS Congress. Remibrutinib is an oral covalent BTK inhibitor under investigation for multiple sclerosis and chronic spontaneous urticaria (CSU), where it blocks BTK signaling to prevent histamine release. While no Phase I or II trials have yet been conducted for multiple sclerosis, remibrutinib is in Phase III development for CSU through the REMODEL-1 and REMODEL-2 trials. Primary completion is expected in 2026, with regulatory submission anticipated in 2027. Earlier Phase IIb CSU data showed favorable safety and tolerability. CNM-Au8 is an oral gold nanocrystal therapy designed to address mitochondrial dysfunction in multiple sclerosis by boosting NAD+ production, enhancing antioxidant capacity, and activating the heat shock factor-1 pathway to support protein homeostasis. Although the VISIONARY-MS Phase II trial was halted early due to COVID-19, CNM-Au8 is being evaluated in the ongoing Phase II REPAIR-MS trial. Results from REPAIR-MS, along with a planned FDA End-of-Phase II meeting in 2025, will inform the design of a global Phase III trial. In April 2025, Clene Nanomedicine presented promising new data at the AAN Annual Meeting, showing meaningful improvements in cognition and visual function from the VISIONARY-MS open-label extension. Masitinib is being developed for progressive multiple sclerosis with a focus on inhibiting mast cells and microglia, key players in chronic neuroinflammation. This approach aims to slow progression in patients with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive multiple sclerosis (SPMS). Following positive results from a Phase IIb/III study, a confirmatory Phase III trial is ongoing. In September 2024, AB Science provided an update on masitinib's development at the ECTRIMS 2024 conference. Discover more about the multiple sclerosis pipeline @ Multiple Sclerosis Clinical Trials The anticipated launch of these emerging therapies for multiple sclerosis are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the multiple sclerosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for Multiple Sclerosis is expected to grow from USD 20 billion in the 7MM in 2024 at a 3.8% CAGR by 2034. This expansion across the 7MM will be driven by the introduction of innovative therapies, remibrutinib, tolebrutinib, fenebrutinib, frexalimab, vidofludimus calcium, CNM-Au8, and masitinib, among others. Furthermore, multiple sclerosis prevalence is rising due to modifiable environmental and lifestyle factors like Epstein-Barr virus, low vitamin D, smoking, obesity, and night shifts, with genetics and geography also contributing. DelveInsight's latest published market report, titled Multiple Sclerosis – Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the multiple sclerosis country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The multiple sclerosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Diagnosed Prevalent Cases of Multiple Sclerosis Gender-specific Diagnosed Prevalent Cases of Multiple Sclerosis Phenotype-specific Diagnosed Prevalent Cases of Multiple Sclerosis EDSS-specific Diagnosed Prevalent Cases of Multiple Sclerosis The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM multiple sclerosis market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this multiple sclerosis market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the multiple sclerosis market. Also, stay abreast of the mitigating factors to improve your market position in the multiple sclerosis therapeutic space. Related Reports Multiple Sclerosis Epidemiology Forecast Multiple Sclerosis Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted multiple sclerosis epidemiology in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan. Multiple Sclerosis Pipeline Multiple Sclerosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple sclerosis companies, including Sanofi, Immunic, InnoCare Pharma, Tiziana Life Sciences, Biogen, Bristol-Myers Squibb, ImStem Biotechnology, Idorsia Pharmaceuticals, among others. Relapsing-Remitting Multiple Sclerosis Market Relapsing-Remitting Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key RRMS companies including Mapi Pharma, Apimeds, Genentech (Roche), Merck, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, among others Relapsing-Remitting Multiple Sclerosis Pipeline Relapsing-Remitting Multiple Sclerosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key RRMS companies, including TG Therapeutics, Novartis, Sanofi, CinnaGen, Immunic, Mapi Pharma, Apimeds, Genentech (Roche), Merck, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, GeNeuro SA, GlaxoSmithKline, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content:
Malaysian Reserve
a day ago
- Malaysian Reserve
A Cosmic Banter: William Shatner & Neil deGrasse Tyson Go Wild on The Late Show with Stephen Colbert
NEW YORK, June 11, 2025 /PRNewswire/ — Space2Sea Alumni—actor William Shatner and astrophysicist Neil deGrasse Tyson— delivered an electrifying and wonderfully chaotic appearance on The Late Show with Stephen Colbert on Monday night, June 9, giving audiences a preview of the spontaneous and profound dialogue that defines their upcoming Wednesday, June 18 live stage event, ROCKING: The Universe is Absurd, presented by FUTURE of SPACE. Viewers watched as Tyson jokingly described his role as needing to 'rescue this man from his existential angst about the Universe,' while Shatner, retorted with sharp wit and boundless energy that left host Stephen Colbert happily letting his guests take the wheel into the 'Shatner Zone'. The discussion veered wildly from the fluid dynamics of penguin poop to a surprisingly deep exploration of ancient spirituality, animism, and the nature of consciousness. This is the 'cosmic banter' audiences can expect in Seattle: a journey connecting the dots between the scientific and the spiritual, the hilarious and the profound. 'Watching Bill and Neil together is electric — they're the ultimate yin and yang,' said Daniel Fox, Co-founder of FUTURE of SPACE. 'One brings cosmic wonder, the other razor-sharp reason, and somehow they meet perfectly in the middle. That's the magic of the show: pure, unscripted chemistry that entertains as much as it enlightens.' 'The energy that was present on The Late Show with Stephen Colbert, is exactly why we created the show,' said Tristan Tanovan-Fox, CEO of FUTURE of SPACE. 'What happens when you put two of our era's most captivating thinkers on stage and let their genuine curiosity lead the way? Their conversation is proof that the biggest, most absurd questions are often the most entertaining and important ones to ask.' Colbert himself praised their riveting chemistry as 'out of this world,' capturing the effortlessly engaging energy the pair brought to the couch. ROCKING: The Universe is Absurd will take place for one night only in Seattle — you won't want to miss it! Website: by: FUTURE of SPACE ( Wednesday, June 18, 2025, 7:30 PM PTWhere: McCaw Hall, 321 Mercer St, Seattle, WA 98109Tickets: Available now exclusively at About 'The Universe Is Absurd'Following their shared journey on the December 2024 Space2Sea Voyage of Legends expedition to Antarctica, Shatner and Tyson reunite onstage for a raw and unscripted cosmic banter. United by boundless curiosity and a passion for discovery, they have forged a dynamic and entertaining 'bromance' — sparring like an old married couple, viewing the world through opposite lenses, and embodying the yin and yang, the left and right sides of the brain. Their connection is as thought-provoking as it is wildly entertaining. About William ShatnerA 94-year-old Canadian-born entertainment legend, William Shatner's storied seven-decade career spans roles like Star Trek's Captain James T. Kirk, Emmy-winning performances in Boston Legal, and record-breaking spaceflight aboard Blue Origin's NS-18 at age 90. About Neil deGrasse TysonRenowned astrophysicist, author, and science communicator, Tyson is the mind behind StarTalk and a popularizer of astronomy who continues Carl Sagan's mission of bringing cosmic understanding to all. About The Late Show with Stephen ColbertA CBS late-night staple, The Late Show blends sharp wit, insightful interviews, and standout musical performances. The June 9 episode opened with 'The Doobie Brothers' and featured unique segments like 'First Drafts with Evie Colbert'. About FUTURE of SPACEFUTURE of SPACE is a media and production company that unites luminaries, innovators, and explorers across disciplines to ignite conversations about the future of humanity. Through experiences like the Space2Sea expeditions, FUTURE of SPACE creates unique intersections between science, storytelling, and human connection — inspiring audiences to embrace exploration not only beyond Earth, but within themselves. Media Contact:Daniel FoxFUTURE of SPACEmedia@ 425-1111
